Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 10/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 8/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | FLT1 | P17948 | 2/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.40 |
| ▸ | STK3 | Q13188 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | FLT4 | P35916 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16090209 | 0.85 | GPR17 (0.51) | HSD17B10GPR17KDM4EALDH1A1HPGD | |
| SCHEMBL547346 | 0.80 | HSD17B10 (0.51) | HSD17B10MAPK1SMN1; SMN2KDRFGFR1 | |
| SCHEMBL25046458 | 0.79 | NPSR1 (0.49) | HSD17B10MAPK1SMN1; SMN2KDRFGFR1 | |
| SCHEMBL11647567 | 0.74 | HSD17B10 (0.49) | HSD17B10MAPK1SMN1; SMN2KDRFGFR1 | |
| SCHEMBL1981272 | 0.72 | KDR (0.51) | HSD17B10KDRFGFR1PDGFRBAPEX1 | |
| SCHEMBL11645293 | 0.72 | HSD17B10 (0.45) | HSD17B10MAPK1SMN1; SMN2KDRFGFR1 | |
| SCHEMBL5612750 | 0.72 | NPSR1 (0.74) | MAPK1SMN1; SMN2ALDH1A1HPGDNPSR1 | |
| SCHEMBL5043454 | 0.70 | MAPK1 (0.71) | MAPK1SMN1; SMN2HPGDNPSR1TDP1 | |
| SCHEMBL28830916 | 0.70 | NPSR1 (0.50) | HSD17B10GPR17KDM4EALDH1A1HPGD | |
| SCHEMBL29793435 | 0.69 | IMPDH2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-9187454-B2 | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof | BOSTON BIOMEDICAL, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | BOSTON BIOMEDICAL, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275033-A1 | INHIBITORS OF KINASES AND CANCER STEM CELLS, AND METHODS OF PREPARATION AND USE THEREOF | MAP3K1, MAP3K6, MAP3K9 | HSD17B10 4193/4885MAPK1 67/4885SMN1; SMN2 3337/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | HSD17B10 2852/4885MAPK1 88/4885SMN1; SMN2 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.